
Confocal interferometric scattering (C-iSCAT) microscopy enables label-free detection of nanoparticles and subcellular structures in live cells, but relating the signal to properties such as size and polarizability remains challenging. These challenges stem from the complex intracellular background amplitude that varies across the imaging volume, which affects the relation between the measured signal and particle properties. Here, we introduce C-SCAT, a confocal scattering microscopy-based measurement and analysis framework for characterizing particle scattering across a wide range of background amplitudes. Using a commercially available confocal microscope, we validate C-SCAT by imaging nanoparticles in controlled environments, spanning standard buffers to cell-like conditions, where the change in C-SCAT signal follows the expected change in particle polarizability. Moreover, we validate that the C-SCAT signal from nanoparticles, to a first-order approximation, remains comparable across the cellular volume. We further demonstrate that the C-SCAT framework enables a model-dependent procedure to estimate the effective polarizability of elongated cellular structures, such as actin filaments, endoplasmic reticulum, and mitochondria, as well as provides information about intracellular dynamics, as exemplified by measuring dynamics near the basal nuclear envelope. Combined with simultaneous fluorescence and forward scattering microscopy, the C-SCAT framework is well-suited for detailed multiparametric characterization of nanoparticle-cell interactions and intracellular dynamics.
Radiotheranostics has achieved clinical maturity, yet preclinical development remains reliant on animal studies. Direct, dynamic measurement of radionuclide distribution offers a distinctive opportunity to develop quantitative New Approach Methodology (NAM) frameworks. We propose integrating human-relevant models, radionuclide sensing, historical biodistribution data and AI-assisted computational prediction. Fit-for-purpose validation, defined contexts of use and domains of applicability, and quantified predictive uncertainty could support reliable translational decisions and enable development beyond animal-first pipelines.
Alanine-serine-cysteine transporter 2 (ASCT2) is a prognostic marker for many cancers. While histological expression is the current clinical metric for ASCT2 evaluation, expression does not scale with activity because post-translational modifications are required for translocation to the plasma membrane. Methods to trace ASCT2 activity ex vivo have not been developed and commercialized. We investigated the utility of imaging alanine as a biomarker for ASCT2 in cancer. Alanine is a major ASCT2 substrate that can be detected in magnetic resonance imaging (MRI) scanners using the chemical exchange saturation transfer (CEST) method. Initially, we demonstrated that its CEST contrast was higher than other major ASCT2 substrates at physiological pH (7.3). We then investigated the sensitivity of alanine-weighted CEST (ALAwCEST) imaging to ASCT2 in vivo using a genetically-engineered patient-derived pancreatic cancer model that we developed. ASCT2 protein expression at the cell surface was 1.6-fold higher in SLC1A5-overexpressing Pa20c cells than naïve Pa20c cells (p = 0.0221). Upon bolus injection of alanine (6 mmol/kg i.v.) in tumor-bearing mice, CEST MRI enhancement was higher in SLC1A5-overexpressing Pa20c tumors than naïve tumors (p < 0.0001). We next investigated the feasibility of ALAwCEST to distinguish prostate tumors with differing levels of ASCT2 content. Enhancement upon injection of 13C3-alanine was more pronounced in LNCaP prostate tumors than DU-145 prostate tumors in vivo (p < 0.0001). Notably, the temporal dynamics of ALAwCEST signal enhancement depended on the volume of the tumor. Mass spectrometric imaging of 13C-labeled metabolites and CEST imaging of metabolite phantoms revealed these differences in in vivo dynamics could be attributed to differences in alanine uptake and metabolism. Overall, we demonstrated the feasibility of ALAwCEST imaging for reporting ASCT2-mediated amino acid uptake in multiple human xenograft tumor models and its utility for cancer applications.
The morphology of astrocytes is closely associated with their ability to support and modulate neural circuit functions; however, its reconstruction from volume electron microscopy (vEM) data remains labor-intensive and computationally resource-intensive, placing substantial barriers on its broader adoption and scalability despite the high spatial resolution of vEM. We present AstroSeg-vEM, a lightweight, astrocyte-centric framework for morphology-preserving astrocyte segmentation, 3D reconstruction, and quantitative morphological analysis in vEM images. AstroSeg-vEM combines transformer-based 2D segmentation with dedicated post-processing methods and operates directly on high-resolution EM sections, making it well suited to anisotropic vEM data and downstream proofreading workflows while preserving the full in-plane resolution of the original EM data. Across four mouse hippocampal datasets representing normal and morphologically defined stress-associated astrocyte ultrastructural states, AstroSeg-vEM demonstrates robust performance and generalization, achieving average Dice and weighted Dice values of 0.92 and 0.95, respectively, on a held-out test dataset. Its lightweight architecture enables efficient, high-fidelity reconstruction on consumer-grade hardware, providing a scalable and accessible platform for large-scale astrocyte ultrastructure analysis and future astrocyte-neuron interaction studies.
Immunotherapy has transformed cancer treatment, yet only a subset of patients achieve durable responses. Because the spatial distribution of T cells within tumors and lymphoid tissues shapes therapeutic outcomes, noninvasive methods capable of monitoring these populations could improve the evaluation of antitumor immune responses. Here, we report the validation of a CD3ε-targeted F(ab’)2 positron emission tomography (PET) probe for noninvasive mapping of T-lymphocytes across tumors and lymphoid tissues and characterize its effects on endogenous T-cell biology. Relative to the full-length IgG construct, the F(ab’)2 format demonstrated more rapid blood clearance, enabled high-contrast imaging within 24 h, produced limited changes in endogenous T-cell populations, and did not measurably impair T-cell activation at imaging-relevant concentrations. CD3ε F(ab’)2 PET detected tumor-infiltrating lymphocytes (TILs) and lymphocytes within the tumor-draining lymph nodes (TDLN) across multiple syngeneic tumor models and in a genetically engineered mouse model of lung adenocarcinoma. In a combination immunotherapy study, tumor uptake distinguished responding from non-responding lesions and detected treatment-associated changes across peripheral lymphoid tissues. These results support CD3ε F(ab’)2 PET as a noninvasive imaging approach that enables assessment of T-cell distribution during tumor growth and therapy, with potential applications in mechanistic studies, biomarker development, and preclinical evaluation of immunomodulatory therapies.